Anti-hepcidin antibodies and uses thereof
AssigneeIntrinsic Lifesciences LLC
InventorsMark Westerman, Vaughn Ostland, Huiling Han, Patrick Gutschow, Keith Westerman, Gordana Olbina
Life of this patent
Estimating the term…
Abstract
The present application relates to antibodies that specifically bind to hepcidin and methods of using the antibodies. Another aspect relates to antibodies which bind hepcidin and regulate iron homeostasis. Another aspect relates to the use of humanized antibodies which bind hepcidin for the treatment of a disease or condition associated with hepcidin.
Claims28
A method of treating a disorder of iron homeostasis associated with elevated hepcidin levels in a subject in need thereof, comprising administering to the subject a composition that comprises an antibody, or antigen-binding fragment thereof, that specifically binds to hepcidin (Hep) or a hepcidin peptide, wherein the antibody, or antigen-binding fragment thereof, comprises a heavy chain Complementary Determining Region 1 (CDR1) encoded by SEQ ID NO:
- 57, a heavy chain CDR2 encoded by SEQ ID NO:
- 60, a heavy chain CDR3 encoded by SEQ ID NO:
- 63, a light chain CDR1 encoded by SEQ ID NO:
- 66, a light chain CDR2 encoded by SEQ ID NO:
- 69, and a light chain CDR3 encoded by SEQ ID NO:
- 72, and an acceptable carrier or excipient.
A method of reducing hepcidin activity in a subject in need thereof, comprising administering to the subject a composition that comprises an antibody, or antigen-binding fragment thereof, that specifically binds to hepcidin (Hep) or a hepcidin peptide, wherein the antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1 encoded by SEQ ID NO:
- 57, a heavy chain CDR2 encoded by SEQ ID NO:
- 60, a heavy chain CDR3 encoded by SEQ ID NO:
- 63, a light chain CDR1 encoded by SEQ ID NO:
- 66, a light chain CDR2 encoded by SEQ ID NO:
- 69, and a light chain CDR3 encoded by SEQ ID NO:
- 72, and an acceptable carrier or excipient.
A method of treating a disorder of iron homeostasis associated with elevated hepcidin levels in a subject in need thereof, comprising administering to the subject a composition that comprises an antibody, or antigen-binding fragment thereof, that specifically binds to hepcidin (Hep) or a hepcidin peptide, wherein the antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1 encoded by SEQ ID NO:
- 56, a heavy chain CDR2 encoded by SEQ ID NO:
- 59, a heavy chain CDR3 encoded by SEQ ID NO:
- 62, a light chain CDR1 encoded by SEQ ID NO:
- 65, a light chain CDR2 encoded by SEQ ID NO:
- 68, and a light chain CDR3 encoded by SEQ ID NO:
- 71, and an acceptable carrier or excipient.
A method of reducing hepcidin activity in a subject in need thereof, comprising administering to the subject a composition that comprises an antibody, or antigen-binding fragment thereof, that specifically binds to hepcidin (Hep) or a hepcidin peptide, wherein the antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1 encoded by SEQ ID NO:
- 56, a heavy chain CDR2 encoded by SEQ ID NO:
- 59, a heavy chain CDR3 encoded by SEQ ID NO:
- 62, a light chain CDR1 encoded by SEQ ID NO:
- 65, a light chain CDR2 encoded by SEQ ID NO:
- 68, and a light chain CDR3 encoded by SEQ ID NO:
- 71, and an acceptable carrier or excipient.
A method of treating an anemia associated with an elevated level of hepcidin in a subject in need thereof, comprising administering to the subject a composition that comprises an antibody, or antigen-binding fragment thereof, that specifically binds to hepcidin (Hep) or a hepcidin peptide, wherein the antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1 encoded by SEQ ID NO:
- 57, a heavy chain CDR2 encoded by SEQ ID NO:
- 60, a heavy chain CDR3 encoded by SEQ ID NO:
- 63, a light chain CDR1 encoded by SEQ ID NO:
- 66, a light chain CDR2 encoded by SEQ ID NO:
- 69, and a light chain CDR3 encoded by SEQ ID NO:
- 72, and an acceptable carrier or excipient.
Dependencies are inferred from the claim text.